KEYTRUDA QLEX

all catalysts(0)

nothing on the calendar yet

News(10)

• The signal that changes everything: understanding MRD in oncology drug development
  Is the cancer truly gone?
  fiercebiotech · 24d ago
• Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
  Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
  biospace · 26d ago
• Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
  “The United States invented this platform and is the only country walking away from it,” Jeff Coller writes of mRNA vaccines.
  stat · 1mo ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 2mo ago
• 5 NextGen winners who went public this year (and which ones are hiring)
  BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.
  biospace · 2mo ago
• Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
  The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…
  biospace · 2mo ago
• Medicare drug price rule may target under-the-skin Keytruda and Opdivo
  For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.
  biopharma_dive · 3mo ago
• What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
  CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...
  endpoints · 4mo ago
• Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC
  Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.
  onclive · 4mo ago
• Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer
  The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.
  onclive · 4mo ago